Navigation Links
Millennium Ranks in the Top 10 Best Biopharma Employers in the World by Science Magazine
Date:10/9/2008

CAMBRIDGE, Mass., Oct. 9 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced it has been named among the best biopharmaceutical companies in the world, according to Science magazine's annual survey of Top Employers in the biotechnology, biopharmaceutical, pharmaceutical and related industries. With a 2008 ranking of eighth, the Company is in the top ten for the first time, moving up from a 2007 ranking of 14.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080827/NEW076LOGO )

"This top ten ranking underscores Millennium's commitment not only to breakthrough science, but also to its employees and overall working environment," said Stephen Gansler, Senior Vice President, Human Resources, Millennium. "It is now more important than ever for us to keep up this positive work culture as we recruit for the hundreds of new additions over the next few months."

Respondents to the web-based survey were asked to rate companies based on 23 driving characteristics, including financial strength, easy adaptation to change and a research-driven environment. The 2008 survey sought to identify the companies with the best reputations as employers, based on nearly 4,000 survey responses from readers of Science and other respondents in industry. Twenty percent of the respondents came from outside the United States, primarily Western Europe, and 92 percent worked in private industry. For the complete business office feature with individual company rankings, please visit: http://sciencecareers.sciencemag.org/career_magazine/previous_issues/articl es/ 2008_10_10/science.opms.r0800061.

Millennium was acquired by Takeda Pharmaceutical Company Limited in May, 2008.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium research, development and commercialization activities are focused in oncology. Additional information about Millennium is available through its website, http://www.millennium.com.

Editor's Note: This press release is also available under the Media section of the Company's website at: http://www.millennium.com

Media Contact:

Manisha Pai

(617)551-7877

manisha.pai@mpi.com


'/>"/>
SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Mark C. Mirken Named New CEO and Chairman of the Board of Millennium Biotechnologies, Inc.
2. Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBCs Drug Discovery & Development of Innovative Therapeutics Conference
3. Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc.
4. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
5. Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion
6. Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
7. Millennium Announces $200,000 Purchase Order From Greek Distributor
8. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
9. Millennium Over-Delivers on 2007 Goals and Financial Guidance
10. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
11. Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a ... biotechnology industries to improve patient outcomes and quality of life, will now be ... are being attributed to new regulatory requirements for all new drug products, including ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The ... transformative for performing systematic gain-of-function studies. , This complement to loss-of-function studies, ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ., ... a Webinar titled, “Pathology is going digital. Is your lab ready?” with Dr. ... best practices and how Proscia improves lab economics and realizes an increase in ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions ... over 5.5 million people each year. Especially those living in larger cities are affected ... based in one of the most pollution-affected countries globally - decided to take action. ...
Breaking Biology Technology:
(Date:4/18/2017)... -- Socionext Inc., a global expert in SoC-based imaging and computing solutions, ... which features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ... will be showcased during the upcoming Medtec Japan at Tokyo Big ... Las Vegas Convention Center April 24-27. ... Click here for an image of ...
(Date:4/11/2017)... , Apr. 11, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global eye tracking market to grow at a CAGR ... Global Eye Tracking Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
Breaking Biology News(10 mins):